医药生物行业周报：《肥胖症诊疗指南（2024年版）》发布，博瑞医药BGM0504 II期减重数据达预期

Investment Rating - The industry investment rating is maintained at "Overweight" [7][13]. Core Insights - The release of the "Obesity Diagnosis and Treatment Guidelines (2024 Edition)" by the National Health Commission is significant, addressing the etiology, epidemiology, definition, diagnosis, assessment, treatment methods, and multidisciplinary collaborative treatment models for obesity [6][7]. - Recent Phase II clinical trial data for BGM0504 from Borui Pharmaceutical shows promising weight loss results, with the 5mg dose group achieving over 5% weight reduction by week 4 and nearly 11% by week 24. The 10mg and 15mg groups showed reductions of over 16% and nearly 19%, respectively [6]. - The proportion of participants achieving significant weight loss (≥5%, ≥10%, ≥20%, and ≥25%) in the various dosage groups indicates high efficacy, with the 15mg group achieving a 100% rate for ≥5% weight loss [6]. - Waist circumference improvements were notable, with the high-dose group showing reductions of 12cm-13cm, surpassing other similar products [6]. - Improvements in lipid metabolism indicators and blood pressure were also observed, with diastolic pressure decreasing by 5mmHg-9mmHg and systolic pressure by 12mmHg-15mmHg [6]. Summary by Sections Industry Overview - The prevalence of overweight and obesity in China is on the rise, making obesity a significant public health issue [7]. Company Focus - Key companies to watch include Borui Pharmaceutical, Lizhu Group, Huadong Medicine, and Zhongsheng Pharmaceutical [7].